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PRECLINICAL STUDIES
Novel Contrast Removal System From
he Coronary Sinus Using an Adsorbing Column
uring Coronary Angiography in a Porcine Model
chiro Michishita, MD, PHD,* Zenzo Fujii, MD, PHD†
okohama and Yamaguchi, Japan
OBJECTIVES This study examined the efficacy of a novel system to remove contrast from the coronary sinus
(CS) using an adsorbing column during coronary angiography.
BACKGROUND Contrast-induced nephropathy (CIN) has become a serious problem for patients with
pre-existing renal insufficiency undergoing percutaneous coronary intervention (PCI).
METHODS Eight swine were studied to evaluate the efficacy of the contrast removal system. A newly
developed 8-F blood suction catheter was inserted into the CS via the right femoral vein. The
venous blood from the CS was transferred into the 500-ml contrast-adsorbing column using
an extracorporeal system. A total of 155 ml of contrast medium was infused selectively into
the coronary artery. Five swine were treated extracorporeally for 90 min using adsorbing
columns, and three were treated without columns as a control group.
RESULTS The mean calculated iodine removal rate was 49.4%. The area under the curve of the iodine
concentration in the group treated with the column was significantly smaller, by 60%, than
that of the group treated without the column (p 0.0003). No significant adverse effects were
observed in the subjects’ vital signs throughout the experiments.
CONCLUSIONS The contrast removal system from CS is effective and safe during coronary angiography in
swine. This technique may be useful for preventing CIN in patients with renal insufficiency
undergoing PCI. (J Am Coll Cardiol 2006;47:1866–70) © 2006 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.080of Cardiology Foundation
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tontrast-induced nephropathy (CIN) is the third leading
ause of hospital-acquired renal insufficiency, accounting for
2% of all cases (1). Acute renal failure requiring dialysis
fter coronary intervention is associated with a poor clinical
utcome, including 22.6% to 35.7% in-hospital mortality
nd 18.8% two-year survival (2,3). Percutaneous coronary
ntervention (PCI) has recently become a common therapy
or coronary artery disease in the drug-eluting stent era. A
arge volume of contrast medium is sometimes administered
n PCI for complicated lesions, including chronic total occlu-
ion. Moreover, diabetes mellitus and diabetic nephropathy are
ecoming more common in Japan and throughout the world.
t has been reported that diabetic patients with baseline
reatinine values of 2.0 mg/dl are at higher risk than
on-diabetic patients for acute renal failure after PCI,
hich is highly correlated with death during the index
ospitalization and after dismissal (4). Even normal renal
unction patients with acute myocardial infarction undergo-
ng primary PCI have a poor prognosis when their condition
s complicated with CIN (5). Baseline renal insufficiency in
atients with acute myocardial infarction undergoing pri-
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005, accepted November 21, 2005.ary PCI is associated with a markedly increased risk of
ortality (6).
In order to prevent CIN, we have invented a novel
ontrast removal system from the coronary sinus (CS) using
n adsorbing column during coronary angiography. The CS
s the main drainage channel of venous blood from the
yocardium. Most of the contrast medium injected into the
oronary artery during coronary angiography is thought to
rain into the CS. In the present study, we have evaluated
he safety and efficacy of the novel contrast removal system
n the porcine model.
ETHODS
nimal preparation. This study was performed under the
upervision of the Animal Research Committee in accor-
ance with the guideline on animal experiments of IVTeC
ompany, NRT Lab, and the Japanese government Animal
rotection and Management Law (No. 105). Eight swine
LWD strain, 3 to 4 months in age, weighing 41.5 to 57.3
g) were studied. Five swine were treated extracorporeally
ith adsorbing columns, and three swine were treated without
olumns as a control group. After premedication with 10 mg
etamine hydrochloride intramuscularly and 2 mg xylazine
ntramuscularly, the animals were intubated and inhalated
ith 5% isoflurane and maintained on mechanical ventila-
ion throughout the study. Administration of 200 IU/kg
eparin was carried out via the ear vein before the extracor-
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May 2, 2006:1866–70 Contrast Removal From Coronary Sinusoreal experiments. If the activated clotting time was below
50 s, a further 200 IU/kg of heparin was injected.
aterials. The contrast-adsorbing columns were obtained
rom Kaneka Corporation (Osaka, Japan). Charcoal beads
oated with a hydroxyethyl methacrylate polymer were used
s the column resin, which was packed into the 500-ml
olumns. The column was pretreated with one liter of saline,
ne liter of saline containing 0.1% glucose, and then one
iter of saline plus 4,000 IU/l heparin. The newly developed
-F blood-suction catheter was also obtained from Kaneka
Fig. 1). Multiple holes were drilled in the distal end of this
atheter for suction, and the catheter was placed in the CS.
he contrast medium (Iopamiron 370) was obtained from
ihon Schering (Osaka, Japan), and was administered with
,000 IU/100 ml heparin. The 2.7-F microcatheters and
xtracorporeal systems were obtained from Kaneka. The
-F Fogarty catheters and 7-F Swan-Ganz catheters were
btained from Edwards Lifesciences (Irvine, California).
tudy design. The new 8-F blood-suction catheter was
quipped with an inner catheter for stiffness and guidewire
ontrol, and was placed under fluoroscopy into the CS via
he right femoral vein in each animal. A Fogarty catheter
as placed into the ostium of the CS via the left jugular vein
nd inflated to block any leakage from the CS into the right
trium. Another balloon was used to block the blood flow
rom the CS into the azygous vein, which connects the CS
o the inferior vena cava in swine but not in human beings
7). The balloon was placed at the end of the CS via the
ight jugular vein using a Swan-Gantz catheter. The venous
lood from the CS was transferred into the contrast-
dsorbing column using an extracorporeal system equipped
ith a roller pump and multiple sensors. The total extra-
orporeal volume including the content volume of the
olumn, tubes, and chambers was 280 ml. A total of 155 
4 ml (mean  SD) contrast medium was infused selec-
ively into the coronary artery at 2.6  0.2 ml/min for 60
in. The time taken for extracorporeal circulation following
nitiation of contrast medium administration was 90 min.
he blood that had passed through the column was re-
urned into the left femoral vein. Blood flow rates in this
ystem were 50 to 80 ml/min, which were adjusted for
uction pressures. Blood samples were withdrawn at 0, 20,
0, 40, 50, 60, and 90 min from the right femoral vein and
rtery and at 0, 10, 20, 30, 40, 50, 60, 65, 75, and 90 min
rom the pre- and post-column.
alculation of iodine concentration. Iodine concentra-
ions at the major points were measured with inductively
oupled plasma optical emission spectrometer analysis (CMC
Abbreviation and Acronyms
CIN contrast-induced nephropathy
CS  coronary sinus
PCI  percutaneous coronary interventionevelopment Department, Nihon Schering) (8). Iodine con- Ientrations at all points were measured with the ultraviolet
ethod, in which the plasma obtained was diluted with saline,
hen the amount of iodine in the plasma was determined by
easuring absorbance at 243 nm. As for the measured value
y both methods, a high correlation coefficient (R2 0.993)
as obtained. The concentration of iodine in the plasma
as calculated from the calibration curve that had been
ade by using the plasma prepared from the same animal
efore administration of contrast medium. The amount of
dsorbed iodine (Iads) was estimated by subtracting the
mount of iodine flowing out of the column (Iout) from the
mount of iodine flowing into the column (Iin) at each
ime point:
IadsIinIout
odine removal rate was estimated by dividing the amount
f adsorbed iodine by the amount of iodine used in the
ontrast medium.
The amount of iodine at each time point flowing out of
he column (Iout) and flowing into the column (Iin) was
alculated by the following formula, using the iodine con-
entration in plasma (C1) at a certain measuring time (t1),
he iodine concentration (C2) at the next time (t2), flow rate
Qb), and hematocrit (Ht) of the animal:
Iin and Iout (C1C2) ⁄ 2 · Qb · (1Ht ⁄ 100) · (t2 t1)
rea under the curve (AUC) of iodine was calculated by the
inear trapezoidal rule.
iochemical analysis of plasma component. A blood cell
ount was done using an automatic blood cell counter. Total
rotein was measured with the biuret method, and albumin
as determined with the BCG kit (Wako Pure Chemical
ndustries Ltd., Osaka, Japan). Creatinine (Cr) was mea-
ured using an enzyme-linked immunosorbent assay. Total
holesterol was measured with cholesterol oxidase/HDAOS
Wako Pure Chemical Industries Ltd.). Potassium, sodium,
nd chlorine were determined with the ionic choice electrode
ISE method; Hitachi Ltd., Tokyo, Japan). Calcium was
ssayed with an OCPC method (Wako Pure Chemical
Figure 1. The 8-F blood-suction catheter.ndustries Ltd.).
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Contrast Removal From Coronary Sinus May 2, 2006:1866–70tatistical analysis. Data are presented as mean values 
EM except for contrast infusion volume and rate, which
re expressed as mean values  SD. High coefficient of
etermination was obtained by doing the regression analysis
y the least square method. The iodine concentrations in
he flow at the inlet and the outlet of the column were
nalyzed by paired Student t test. The iodine concentrations
n peripheral blood resulting from the use of the column and
UC in femoral venous blood treated with or without the
olumn were analyzed by a non-paired Student t test.
ignificance was assigned to a value of p  0.05. These
nalyses were performed with Stat View J-4.51.2 (SAS
nstitute, Cary, North Carolina).
ESULTS
odine concentrations of pre- and post-column. The iodine
oncentrations at the outlet of the column during the infusion
f the contrast medium into the coronary artery (10 to 60 min
irculation) were significantly lower than those at the inlet of
he column, which were equal to those in the blood-suction
atheter (p  0.001) (Fig. 2). The mean iodine removal rate
as 49.4% in the group treated with the column, accounting
or 72% of the contrast medium that passed through the
olumn (Fig. 3). This column was theoretically saturated with
20 ml contrast medium at maximum.
igure 2. Effects of column use on iodine concentration. Iodine concentrat
irculation. Values are presented as mean  SEM (n  5). *p  0.001; †Figure 3. Removal of contrast medium using the column. Values are presentedodine concentrations of peripheral vein and artery. The
odine concentrations in the femoral vein and artery
hroughout the extracorporeal circulation (20 to 90 min)
n the group treated with the column were significantly
ower than those in the group treated without the column
p  0.0005; p  0.003) (Fig. 4). The AUC of the iodine
oncentration in the group with the column was signifi-
antly smaller by 60% than that of the group without the
olumn (p  0.0003) (Fig. 5).
ffects of the system on biochemical data and vital
igns. No significant differences in the red blood cell, white
lood cell, or platelet counts, hematocrit levels, or the blood
evels of total protein, albumin, total cholesterol, Cr, K, Na,
l, or Ca were seen between the extracorporeal experiments
ith and without the column (Table 1). No significant
dverse effects on the subjects’ vital signs, including blood
ressure, body temperature, and electrocardiogram data,
ere observed throughout the experiments (data not shown).
ISCUSSION
uman application of the system on contrast removal.
he system used in the present study efficiently removed
ontrast medium injected into the coronary artery from the
S. Using the mean iodine removal rate of 49.4%, only 75.9
l contrast medium would burden the kidney when the
ere measured in the flow at the inlet and the outlet of the column during
0.05; inlet vs. outlet, respectively.ions was mean  SEM (n  5). The solid lines show the individual values.
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May 2, 2006:1866–70 Contrast Removal From Coronary Sinusontrast removal system and 150 ml contrast medium,
njected only into the coronary artery during angiography or
CI, are used. The iodine removal rate would be reduced to
ome extent by not using the proximal balloon block with
he Fogarty catheter for safety reasons in human applica-
ions and also by the bolus infusion of the contrast medium
nto the coronary artery, as in actual coronary angiography
nd PCI procedures. The new 8-F blood-suction catheter
or the CS can be easily placed from the femoral vein into
he CS under fluoroscopic guidance without the adminis-
ration of contrast medium. Multiple side-holes in the distal
atheter would help to withdraw CS flow efficiently and
afely in human application from the left coronary artery as
ell as the right coronary artery, which mainly drains into or
igure 4. Changes of iodine concentrations in peripheral blood resulting fr
p  0.0005; †p  0.003.
igure 5. Area under the curve in femoral venous blood treated with or
ithout the column. Values are presented as mean  SEM (n  5 or 3);v
 0.0003. AUC0-90  area under the curve of iodine concentrations in
he femoral vein from 0 to 90 min of the extracorporeal circulation time.djacent to the ostium of the CS. Because the communica-
ion between the azygous vein and the distal coronary sinus
n swine does not normally exist in human beings, a distal
alloon block would not be needed in human applications.
fficacy of contrast removal from the coronary sinus.
ompared with continuous hemofiltration (9), the only
roven adjunctive therapy for the efficient prevention of
IN, our system has several advantages. The system would
heoretically be more effective and essential for the removal of
ontrast medium because it could remove most of the injected
ontrast medium directly from the CS, with only a small
mount of leakage into the systemic circulation. The results in
his experiment indicate that almost all of the contrast medium
njected into the coronary artery is drained into the CS in swine
hen proximal and distal blocking balloons are used. There-
ore, our system using coronary sinus suction prevents the first
assage of contrast medium through the renal arteries better
han any other system.
fficacy of selective contrast removal. Our system uses a
elective adsorbing column to remove the contrast medium.
sing hemofiltration systems, some plasma components are
nevitably lost. In our system, no significant losses of plasma
omponents were observed with great efficiency of contrast
emoval because the column used in the system has an affinity
o and selectively adsorbs the contrast medium. In terms of
fficacy and safety, selective plasmapheresis, consisting of a
elective adsorbing column, directly or after plasma separation
s best. In clinical practice, many adsorbing therapies are used
ecause each adsorbing column has a unique affinity and
electivity, compared with hemofiltration and hemodialysis. In
articular, low-density lipoprotein (LDL)-apheresis has been
sed to treat patients with hypercholesterolemia, coronary
rtery disease, cholesterol embolism syndrome, and peripheral
rtery disease (10–12). For the treatment of coronary artery
isease with PCI, numerous clinical experiences of LDL-
pheresis, even before and after PCI, have been compiled (13).
ompared with LDL-apheresis, which requires a plasma
eparator and an adsorbing column with an extracorporeal
e use of the column. Values are presented as mean  SEM (n  5 or 3).om tholume of more than 400 ml, our system consists of a
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Contrast Removal From Coronary Sinus May 2, 2006:1866–70irect hemoperfusion column without a plasma separator
nd requires an extracorporeal volume of only 280 ml,
uggesting that this system may be safely used in human
eings even during PCI (10,11).
dvantage of time- and cost-saving treatment. Our sys-
em offers time-saving benefits because it only needs to be used
uring PCI or angiography and does not require any pre-or
ost-procedures. Marenzi et al. (9) reported that continuous
emofiltration needed to be performed for 4 to 8 h before PCI
nd 18 to 24 h after PCI. Our system, which can be used only
uring PCI or angiography and can be used only in a
atheterization laboratory, thus has both time and cost benefits.
f more time and effort were required to place the blood-
uction catheter in the CS, the system would not be applicable
n human beings. In fact, the catheter can be easily placed in
he CS without administering contrast medium.
onclusions. The present study confirms that the novel
ontrast removal system from the CS using the adsorbing
olumn is effective and safe in swine during coronary angiog-
aphy. The indication of this system may have potential in
uman patients with pre-existing renal insufficiency, dia-
etic nephropathy, or many risk factors who are undergoing
CI for complicated lesions.
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Table 1. Comparison of Biochemical Data for
Column
With Column (n  4)
Before After %
RBC, 104/ml 519  37 535  27
WBC, 102/ml 191  16 167  23
PLT, 104/ml 28.1  6.7 23.1  7.0
Hct, % 31.9  2.0 32.9  1.4
TP, g/dl 6.0  0.5 5.8  0.4
A/G 1.0  0.2 1.0  0.2
ALB, g/dl 2.9  0.3 2.8  0.2
TC, mg/dl 62  2 60  1
Cr, mg/dl 1.11  0.14 1.06  0.11
Na, mEq/l 145  2 143  1
Cl, mEq/l 104  1 101  1
K, mEq/l 4.1  0.1 4.7  0.1
Ca, mg/dl 10.2  0.5 10.4  0.6
Values are presented as the mean  SEM.
A/G  albumin/globulin; ALB  albumin; Cr  creatin
TC  total cholesterol; TP  total protein; WBC  white-mail: yk411015@fsinet.or.jp or michishita-i@amy.hi-ho.ne.jp.EFERENCES
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